Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study-Reference-Cited by-同舟云学术

Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study

Published:2018-06-22 Issue:8 Volume:48 Page:736-742
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Ohmachi Ken¹,Ando Kiyoshi¹,Kinoshita Tomohiro²,Kumagai Kyoya³,Hatake Kiyohiko⁴,Ishikawa Takayuki⁵,Teshima Takanori⁶,Kato Koji⁷,Izutsu Koji⁸,Ueda Eisuke⁹,Nakai Kiyohiko⁹,Kuriki Hiroshi⁹,Tobinai Kensei¹⁰

Affiliation:

1. Tokai University School of Medicine, Kanagawa, Japan

2. Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Aichi, Japan

3. Division of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan

4. The Cancer Institute Hospital of JFCR, Tokyo, Japan

5. Department of Hematology, Kobe City Medical Center General Hospital, Hyogo, Japan

6. Hokkaido University Faculty of Medicine, Hokkaido, Japan

7. Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan

8. Department of Hematology, Toranomon Hospital, Tokyo, Japan

9. Clinical Pharmacology Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan

10. National Cancer Center Hospital, Tokyo, Japan

Funder

Chugai Pharmaceutical Co Ltd

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/48/8/736/25536344/hyy087.pdf

Reference22 articles.

1. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity;Mössner;Blood,2010

2. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models;Herter;Mol Cancer Ther,2013

3. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies;Tobinai;Adv Ther,2017

4. Obinutuzumab for the first-line treatment of follicular lymphoma;Marcus;N Engl J Med,2017

5. Immunochemotherapy with obinutuzumab or rituximab in previously untreated folllicular lymphoma in the randomised phase III GALLIUM study: analysis by chemotherapy regimen;Hiddemann;Hematol Oncol,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

2. Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial;Brazilian Journal of Medical and Biological Research;2024

3. Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia;BMC Cancer;2022-02-06